Nice pop impulse recently. Most resiatnce I see is around 4$. As of now holding some solid support based off my favorite indicators. If w can pop 2.88 and hold should see another run. Don’t think it’s over yet, cpuld
Be just the beginning. 1 hour potential double bottom. Stops below 2.50$
Genprex Receives U.S. FDA Fast Track Designation for REQORSA™️ Immunogene Therapy in Combination With Keytruda®️ for the Treatment of Non-Small Cell Lung Cancer
Second FDA Fast Track Designation Further Validates the Potential of REQORSA
AUSTIN, Texas, January 03, 2022--(BUSINESS WIRE)--Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage...
GNPX: Genprex, Inc.
2022-01-03 08:00:00
Genprex Receives U.S. FDA Fast Track Designation for REQORSA™ Immunogene Therapy in Combination With Keytruda® for the Treatment of Non-Small Cell Lung Cancer
MID-TERM: Trying to hold a support with potential classic bullish divergence on the 4hr and potential hidden bullish divergence on the daily, if it pivots here. (not financial advice)
huge amazing wedge!! this is the third time that price has made it to $4.25. GNPX has been rejected at this price twice before. Third time is winner yes?
About Genprex Inc
Genprex, Inc. operates as a biotechnology company. The Company discovers and develops immunogene therapies for cancer treatment, as well as provides clinical research, gene therapies, consulting, and other related medical services. Genprex serves customers in the United States.
Bloomberg Profile: https:...
Daily could not close above the line we got drawn above it and then lost the low so we are in own trend... as far as i see this stock is ready to dump!
**Disclaimer** the content on this analysis is subject to change at any time without notice, and is provided for the sole purpose of assisting traders to make independent investment decisions.
Traders!! if you...
Genprex, Inc. is a clinical stage gene therapy company, which engages in the development of novel proprietary technology platform for the treatment of cancer. It develops the Oncoprex immunogene therapy which targets the non-small cell lung cancer and other solid tumors. The company was founded by J. Rodney Varner in April 2009 and is headquartered in Austin,...
Genprex, Inc. is a clinical stage gene therapy company, which engages in the development of novel proprietary technology platform for the treatment of cancer. It develops the Oncoprex immunogene therapy which targets the non-small cell lung cancer and other solid tumors. The company was founded by J. Rodney Varner in April 2009 and is headquartered in Austin,...
